6-K
GSK Publishes Provisional Dividend Dates for 2027
6-K
GSK plc Announces Total Voting Rights and Issued Share Capital as of October 31, 2026
6-K
GSK Delivers Strong Q3 2026 Results with 5% Sales Growth and Reaffirms Guidance
6-K
Ris-Rez achieves positive Phase III results in osteosarcoma in China, reducing disease progression or death risk by 67%
6-K
GSK plc Announces Share Transaction by PDMR Maya Martinez-Davis
6-K
GSK Announces Positive Phase II AZUR-1 Trial Data for Jemperli in Rectal Cancer